Browsing Tag
Inc.
196 posts
Hyperscale Data fortifies balance sheet with $125m raise, doubling down on bitcoin-backed AI expansion
Find out how Hyperscale Data’s $125 million raise is powering its bold bitcoin-backed AI infrastructure expansion.
Can ECARX challenge legacy Tier-1s in the intelligent cockpit race? A look at global platform shifts
ECARX pushes into the intelligent cockpit market, challenging traditional Tier‑1 automotive suppliers with full‑stack digital cabin solutions. Read how.
Is Merck building the next great cardiometabolic franchise? A closer look at WINREVAIR, enlicitide and Ohtuvayre
See how Merck is building a cardiometabolic growth engine with WINREVAIR, enlicitide and Ohtuvayre—and what it means for investors.
Netflix just split its stock 10-for-1—here’s what it means for shareholders and employees
Find out how Netflix’s 10-for-1 stock split is reshaping investor access, employee ownership, and shareholder sentiment today!
Can Merck sustain its oncology-led momentum? Keytruda, WINREVAIR, and pipeline drive Q3 beat
Merck’s Q3 2025 results beat expectations on Keytruda strength and a rising pipeline. Explore what’s driving EPS upgrades and future growth bets.
BWXT expands into modular nuclear manufacturing with Rolls-Royce SMR steam generator contract
BWXT signs steam generator contract with Rolls‑Royce SMR to scale modular nuclear components globally. Find out what this means for nuclear manufacturing now.
Merck’s KEYTRUDA + WELIREG combo shows major disease-free survival benefit in clear cell renal cell carcinoma after surgery
Find out how Merck’s KEYTRUDA + WELIREG combo improved disease-free survival after kidney cancer surgery and what it means for the oncology market.
Merck and Eisai announce major win as Welireg plus Lenvima delays progression in advanced renal cell carcinoma
Find out how Merck and Eisai’s Welireg + Lenvima combo redefines kidney cancer care after immunotherapy and what this major Phase 3 win means for investors.
Aeluma makes bold move to boost in-house semiconductor production with new equipment buy
Find out how Aeluma’s latest equipment acquisition could redefine its semiconductor manufacturing strategy and accelerate commercialization.
Merck’s kidney cancer breakthrough hits one target—Will it be enough to change how doctors treat RCC?
Merck and Eisai’s new kidney cancer combination met a key Phase 3 goal. Discover what it means for patients, investors, and the oncology landscape.